Drug Trial Radar · NCT05083468
The Safety, Tolerability, and Pharmacokinetics (PK) of SR750 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Nov 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
83
Actual
Start
Oct 29, 2021
Primary completion
Oct 14, 2022
Study completion Oct 14, 2022
Sponsor
- Lead sponsor
- Shanghai SIMR Biotechnology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 19, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is to evaluate the safety, tolerability, and PK of SR750 in healthy volunteers.
Conditions
- Healthy Volunteers
Interventions
SR750 tabletDrug
The volunteers will be orally administrated by single or multiple dose of SR750 tablet with 240 mL water.
matching placeboDrug
The volunteers will be orally administrated by single or multiple dose of matching placebo with 240 mL water.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The frequency and severity of AEs in healthy volunteers administrated with single and repeated oral doses of SR750Time frame: Up to Day15 for the safety follow up since Day1
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nucleus Network Pty Ltd
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.